ritanserin has been researched along with Anxiety in 21 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the ability of ritanserin, a 5-HT2 antagonist, to modify ethanol withdrawal (EW) symptoms in two animal models of anxiety: the elevated plus-maze (EPM) and the pentylenetetrazol (PTZ) discrimination assay." | 7.70 | Effects of ritanserin on ethanol withdrawal-induced anxiety in rats. ( Gatch, MB; Lal, H; Wallis, CJ, 2000) |
| " Single doses of 5-HT2 antagonists, mianserin (5mg/kg) and ritanserin (1mg/kg), effectively ameliorated withdrawal anxiety in the rat, returning behavioural function in the social interaction test and elevated plus maze to levels comparable to vehicle-treated animals." | 3.73 | Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists. ( Begg, DP; Hallam, KT; Norman, TR, 2005) |
| "This study investigated the ability of ritanserin, a 5-HT2 antagonist, to modify ethanol withdrawal (EW) symptoms in two animal models of anxiety: the elevated plus-maze (EPM) and the pentylenetetrazol (PTZ) discrimination assay." | 3.70 | Effects of ritanserin on ethanol withdrawal-induced anxiety in rats. ( Gatch, MB; Lal, H; Wallis, CJ, 2000) |
| "The effect of intracerebrally injected propranolol was measured in the elevated plus-maze, an animal model of anxiety." | 3.67 | Serotonergic mediation of the anxiolytic effect of intracerebrally injected propranolol measured in the elevated plus-maze. ( Audi, EA; de-Oliveira, CE; Graeff, FG, 1989) |
| "Ritanserin was given at a daily dose of 10 mg for 28 days and was preceded (10 days) and followed (2 days) by a placebo." | 2.67 | The effects of ritanserin on mood and sleep in abstinent alcoholic patients. ( Alterwain, P; Alvariño, F; Estévez, F; Giusti, M; Labraga, P; Monti, JM; Olivera, S, 1993) |
| " Ritanserin discontinuation following chronic dosing in healthy volunteers does not appear to be associated with withdrawal symptoms." | 2.67 | Absence of withdrawal effects of ritanserin following chronic dosing in healthy volunteers. ( Ashton, CH; Emanuel, MB; Hammond, GL; Kamali, F; Rawlins, MD; Stansfield, SC, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 10 (47.62) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ponzoni, L | 1 |
| Sala, M | 1 |
| Braida, D | 1 |
| Stachowicz, K | 3 |
| Kłodzińska, A | 1 |
| Palucha-Poniewiera, A | 1 |
| Schann, S | 1 |
| Neuville, P | 1 |
| Pilc, A | 3 |
| Brüning, CA | 1 |
| Prigol, M | 1 |
| Roehrs, JA | 1 |
| Nogueira, CW | 1 |
| Zeni, G | 1 |
| Overstreet, DH | 1 |
| Knapp, DJ | 1 |
| Moy, SS | 1 |
| Breese, GR | 1 |
| Begg, DP | 1 |
| Hallam, KT | 1 |
| Norman, TR | 1 |
| Chojnacka-Wójcik, E | 2 |
| Kłak, K | 1 |
| Gołembiowska, K | 1 |
| Sowa, M | 1 |
| Nowak, G | 1 |
| Gonzalez, MI | 2 |
| Farabollini, F | 2 |
| Albonetti, E | 2 |
| Wilson, CA | 2 |
| Monti, JM | 1 |
| Alterwain, P | 1 |
| Estévez, F | 1 |
| Alvariño, F | 1 |
| Giusti, M | 1 |
| Olivera, S | 1 |
| Labraga, P | 1 |
| Siddiqui, A | 1 |
| Guimarães, FS | 1 |
| Mbaya, PS | 1 |
| Deakin, JF | 1 |
| Gatch, MB | 1 |
| Wallis, CJ | 1 |
| Lal, H | 1 |
| Kamali, F | 1 |
| Stansfield, SC | 1 |
| Ashton, CH | 1 |
| Hammond, GL | 1 |
| Emanuel, MB | 1 |
| Rawlins, MD | 1 |
| Danjou, P | 1 |
| Warot, D | 1 |
| Hergueta, T | 1 |
| Lacomblez, L | 1 |
| Bouhours, P | 1 |
| Puech, AJ | 1 |
| Almeida, SS | 1 |
| de Oliveira, LM | 1 |
| Graeff, FG | 2 |
| Stutzmann, JM | 1 |
| Eon, B | 1 |
| Darche, F | 1 |
| Lucas, M | 1 |
| Rataud, J | 1 |
| Piot, O | 1 |
| Blanchard, JC | 1 |
| Laduron, PM | 1 |
| Seibyl, JP | 1 |
| Krystal, JH | 1 |
| Price, LH | 1 |
| Woods, SW | 1 |
| D'Amico, C | 1 |
| Heninger, GR | 1 |
| Charney, DS | 1 |
| Audi, EA | 1 |
| de-Oliveira, CE | 1 |
| Colpaert, FC | 1 |
| Meert, TF | 1 |
| Niemegeers, CJ | 1 |
| Janssen, PA | 1 |
| Gardner, CR | 1 |
5 trials available for ritanserin and Anxiety
| Article | Year |
|---|---|
The effects of ritanserin on mood and sleep in abstinent alcoholic patients.
Topics: Adult; Affect; Alcoholism; Anxiety; Humans; Male; Middle Aged; Ritanserin; Sleep; Sleep Initiation a | 1993 |
Ritanserin facilitates anxiety in a simulated public-speaking paradigm.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety; Female; Humans; Male; Receptors, Serotonin; Ritanse | 1997 |
Absence of withdrawal effects of ritanserin following chronic dosing in healthy volunteers.
Topics: Adolescent; Adult; Anxiety; Depression; Double-Blind Method; Female; Humans; Male; Ritanserin; Singl | 1992 |
Comparative study of the psychomotor and antistress effects of ritanserin, alprazolam and diazepam in healthy subjects: some trait anxiety-independent responses.
Topics: Acoustic Stimulation; Adult; Alprazolam; Anxiety; Diazepam; Double-Blind Method; Feedback; Flicker F | 1992 |
Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects.
Topics: Adult; Anxiety; Data Interpretation, Statistical; Double-Blind Method; Growth Hormone; Humans; Hydro | 1991 |
16 other studies available for ritanserin and Anxiety
| Article | Year |
|---|---|
Ritanserin-sensitive receptors modulate the prosocial and the anxiolytic effect of MDMA derivatives, DOB and PMA, in zebrafish.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Hallucinogens; Motor Activity; N-Methyl-3,4 | 2016 |
The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Cyclopentanes; Depression; Flumazenil; | 2009 |
Involvement of the serotonergic system in the anxiolytic-like effect caused by m-trifluoromethyl-diphenyl diselenide in mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Brain; Dose-Response Relationship, Drug; Female; Lighting; Lo | 2009 |
A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats.
Topics: Aminopyridines; Animals; Anxiety; Buspirone; Dose-Response Relationship, Drug; Ethanol; Ethylamines; | 2003 |
Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Diazepam; Disease Models, Animal; Interpers | 2005 |
Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Conflict, Psychological; Cyclopentanes; Dis | 2007 |
Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Dose-Response Relationship, Drug; Injection | 2007 |
Interactions between 5-hydroxytryptamine (5-HT) and testosterone in the control of sexual and nonsexual behaviour in male and female rats.
Topics: Amphetamines; Animals; Anxiety; Behavior, Animal; Exploratory Behavior; Female; Male; Motor Activity | 1994 |
Neonatal organizational effects of the 5-HT2 and 5-HT1A subsystems on adult behavior in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Animals; Animals, Newborn; Anxiety; Behavior, | 1996 |
[Risperdal: a new hope for schizophrenic patients?].
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Humans; Ritanserin; Schizophrenia; Serotonin Ant | 1994 |
Effects of ritanserin on ethanol withdrawal-induced anxiety in rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Central Nervous System Depressants; Discrimination Learning; | 2000 |
Early life protein malnutrition changes exploration of the elevated plus-maze and reactivity to anxiolytics.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Diazepam; Dose-Response Relationship, Drug; Exploratory Behav | 1991 |
Are 5-HT2 antagonists endowed with anxiolytic properties in rodents?
Topics: Animals; Anti-Anxiety Agents; Anxiety; Carbolines; Cerebral Cortex; Cyclic S-Oxides; Dose-Response R | 1991 |
Serotonergic mediation of the anxiolytic effect of intracerebrally injected propranolol measured in the elevated plus-maze.
Topics: Animal Testing Alternatives; Animals; Anxiety; Exploratory Behavior; Injections, Intraventricular; M | 1989 |
Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rat.
Topics: 5-Hydroxytryptophan; Animals; Anti-Anxiety Agents; Anxiety; Chlordiazepoxide; Diazepam; Disease Mode | 1985 |
Recent developments in 5HT-related pharmacology of animal models of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Buspirone; Disease Models, Animal; Piperidines; Pyrimidines; | 1986 |